Skip to main content
Pfizer10-Q: Compliance burden

Pfizer reaches binding agreements with U.S. Government on drug pricing, discounts, and domestic manufacturing commitments

Source: Autobound Signal API · 104 signals tracked for Pfizer · updated

Get Pfizer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Pfizer this week? Use Autobound signals for pfizer.com.

What happened

Pfizer agreed to binding arrangements with the U.S. Government featuring commitments to make drug prices more comparable to other developed countries, provide patient discounts, and invest further in U.S. manufacturing to secure a zero tariff rate under Section 232 through January 20, 2029. This may drive significant compliance and manufacturing supply chain adjustments.

Source

SEC EDGARAug 4, 2026

Quarterly report (Form 10-Q)

Pfizer 10-Q for Quarter ended Jun 28, 2026

Filing excerpt

We have reached final binding agreements with the U.S. Government, ratifying the arrangements first announced in September 2025. Under these agreements, we have voluntarily committed to implement measures designed to make certain drug prices for U.S. patients more comparable to those in other developed countries, allow U.S. patients to purchase certain medicines at significant discounts to current retail prices and further invest in our U.S. manufacturing. Pursuant to the agreements, the applicable tariff rate under the April 2, 2026 Section 232 Executive Order for Pfizer products will be zero until January 20, 2029.

sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Compliance burden

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Jun 28, 2026
Fiscal year end
06/28
Filed
Aug 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
0% (tariff rate applicable under Section 232 until January 20, 2029)

Details

CIK
78003
Accession number
0000078003-26-000095
Timeframe
Multi year
Quarter
Q2
Filing year
2026
Period end date
Jun 28, 2026
Why it matters
GRC tools needed
Signal category
Risk

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Neutral
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
complianceBurden

Use this data

Get every 10-Q signal for Pfizer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pfizer this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/68c07798-70b6-429b-9d51-6979d8a0ad9c returns this record as JSON. POST /v1/companies/enrich returns every signal for pfizer.com.

{
  "signal_id": "68c07798-70b6-429b-9d51-6979d8a0ad9c",
  "signal_type": "sec-10q",
  "signal_subtype": "complianceBurden",
  "detected_at": "2026-11-09T06:32:59.849+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "detail": "Pfizer agreed to binding arrangements with the U.S. Government featuring commitments to make drug prices more comparable to other developed countries, provide patient discounts, and invest further in U.S. manufacturing to secure a zero tariff rate under Section 232 through January 20, 2029. This may drive significant compliance and manufacturing supply chain adjustments.",
    "metrics": {
      "pct": 0,
      "timeframe": "multi_year",
      "pct_context": "tariff rate applicable under Section 232 until January 20, 2029"
    },
    "quarter": "Q2",
    "summary": "Pfizer reaches binding agreements with U.S. Government on drug pricing, discounts, and domestic manufacturing commitments",
    "excerpts": "We have reached final binding agreements with the U.S. Government, ratifying the arrangements first announced in September 2025. Under these agreements, we have voluntarily committed to implement measures designed to make certain drug prices for U.S. patients more comparable to those in other developed countries, allow U.S. patients to purchase certain medicines at significant discounts to current retail prices and further invest in our U.S. manufacturing. Pursuant to the agreements, the applicable tariff rate under the April 2, 2026 Section 232 Executive Order for Pfizer products will be zero until January 20, 2029.",
    "relevance": 0.75,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm",
    "filing_date": "2026-08-04",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/28",
    "period_end_date": "2026-06-28",
    "sales_relevance": "GRC tools needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.